Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression

Fig. 2

Desloratadine targets the NMT1 protein, which contributes to the progression of HCC. a Schematic diagram of the DARTS method. b The 5 candidate proteins identified by mass spectrometry analysis. c IHC staining showing NMT1 expression in clinical HCC tissues and adjacent noncancerous tissues. d NMT1 expression in 180 HCC tumor tissues and 176 matched nontumor tissues. e The NMT1 expression level was significantly negatively correlated with the overall survival rate of HCC patients (low NMT1 expression: No and Weak; high NMT1 expression: Moderate and Strong). f Cell viability assay showing the effect of NMT1 expression on the viability of HCC cells. g Effects of NMT1 expression on the migration and invasion of HCC cells. h Image of subcutaneous xenografts derived from nude mice (n = 6 tumors per experimental group) and xenograft growth curves. i Representative images of Ki67 staining in tumor tissue. Bars, SDs; *p < 0.05; **p < 0.01, ***p < 0.001

Back to article page